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Summary
Induction of apoptotic cell death in response to chemotherapy and other external stimuli has proved extre-
mely difficult in melanoma, leading to tumor progression, metastasis formation and resistance to therapy.
A promising approach for cancer chemotherapy is the inhibition of proteasomal activity, as the half-life of the
majority of cellular proteins is under proteasomal control and inhibitors have been shown to induce cell death
programs in a wide variety of tumor cell types. 4-Nerolidylcatechol (4-NC) is a potent antioxidant whose cyto-
toxic potential has already been demonstrated in melanoma tumor cell lines. Furthermore, 4-NC was able to
induce the accumulation of ubiquitinated proteins, including classic targets of this process such as Mcl-1. As
shown for other proteasomal inhibitors in melanoma, the cytotoxic action of 4-NC is time-dependent upon
the pro-apoptotic protein Noxa, which is able to bind and neutralize Mcl-1. We demonstrate the role of 4-NC
as a potent inducer of ROS and p53. The use of an artificial skin model containing melanoma also provided
evidence that 4-NC prevented melanoma proliferation in a 3D model that more closely resembles normal
human skin.
Introduction
Melanoma is the most aggressive skin cancer with the
highest mortality. The main risk factor for its development
is UV exposure, although individuals with a family history
ofmelanoma have a 30- to 70-fold higher risk of developing
the disease (Greinert, 2009; Ibrahim and Haluska, 2009).
Metastatic malignant melanoma is largely refractory to
chemotherapy and radiotherapy, and has a poor prognosis.
The survival rate is of 6 months to 5 yr in <5% of cases.
Therefore, efforts to generate new therapeutic strategies
are essential (Gray-Schopfer et al., 2007; Hersey and
Zhang, 2001; Miller et al., 2009; Paraiso et al., 2010;
Soengas and Lowe, 2003; Sorolla et al., 2008).
Although new melanoma treatments such as the
B-raf inhibitor (PLX 4032) and the anti-CTLA4 antibody
Significance
4-Nerolidylcatechol (4-NC) is known to induce G1 cell cycle arrest, decrease the activity of MMPs and
induce apoptotic cell death. In this study we demonstrate the mechanism of action of this compound
starting with the formation and accumulation of ROS, leading to DNA damage, induction of p53, an
increase in Noxa that is able to bind and neutralize Mcl-1 followed by poteasomal inhibition, culminating
in caspase-dependent apoptosis. Our data now suggest that the 4-NC compound can potentially be used
as a chemotherapeutic agent in the treatment of human melanoma.
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(IPILIMUMAB) have been associated with a clinical ben-
efit (Flaherty et al., 2010; Hodi et al., 2010), acquired
and intrinsic resistance remains a major limiting factor
for long-term disease management (Smalley and Son-
dak, 2010). Current research efforts are focused upon
the development of combination therapy strategies and
the identification of new classes of therapeutic agents.
Another new therapeutic approach for cancer chemo-
therapy includes pharmacologic inhibitors which, for
example, block the ubiquitin-proteasome system and
inhibit the autophagy process (Ferna´ndez et al., 2006;
Jesenberger and Jentsch, 2002; Roberti et al., 2011;
Tormo et al., 2009).
In the past decade, pharmacologic inhibitors of the
ubiquitin-proteasome pathway have been tested as anti-
tumoral therapeutic agents by inducing cell death both
in vitro and in vivo. The inhibition of proteasome activity
is expected to be a new strategy for cancer chemother-
apy because of its ability to overcome chemoresistant
pathways as well as to potentiate the activity of other
cancer therapeutics.
The ubiquitin proteasome system (UPS) is responsible
for the degradation of the majority of regulatory proteins
in eukaryotic cells (Crusio et al., 2010; Nikiforov et al.,
2007; Sorolla et al., 2008). Interestingly, many pro-onco-
genic factors, e.g. transcriptional factors such as nuclear
factor jb (NF-jb), as well as both pro- and anti-apoptotic
factors, are also controlled by the proteasome (Crusio
et al., 2010; Ferna´ndez et al., 2006; Jesenberger and
Jentsch, 2002).
4-Nerolidylcatechol (4-NC), a compound initially
extracted from the plant Pothomorphe umbellata L. Miq
(PU), was first described as a potent in vitro antioxidant
(Barros et al., 1996). This compound showed high anti-
oxidant activity when compared with a-tocopherol,
reported to be one of the most active antioxidants,
interfering with one or more steps of the process of
propagation of lipid peroxidation (Barros et al., 1996;
Desmarchelier et al., 2000). It was demonstrated that
the PU compound 4-NC and its antioxidant activity play
a significant role in the prevention of damage caused by
oxidative stress in skin, suggesting its application in cos-
metic formulations (Ropke et al., 2002). In 2002, Ropke
and co-workers demonstrated the high percutaneous
absorption of 4-NC in a gel formulation (0.1% 4-NC),
leading to high levels of the compound in skin. Matrix
metalloproteinases (MMPs) 2 and 9 were also inhibited
in the presence of 4-NC in a skin photoaging model in
mice (Ropke et al., 2006).
We have previously demonstrated the cytotoxic activity
of 4-NC in melanoma cell lines. The compound induced
G1 cell cycle arrest, decreased MMP activity and induced
cell death by apoptosis (Brohem et al., 2009) in melanoma
lines in vitro.
In the present work we evaluated the growth inhibi-
tory effects of 4-NC and its ability to induce cell death
in a broad panel of cell lines derived from metastatic
melanoma, and uncovered a new role of 4-NC as a pro-
teasomal inhibitor. 4-NC induced the accumulation of
ubiquitinated proteins, including classic targets of this
process such as Mcl-1. As shown for other proteasomal
inhibitors in melanoma, the cytotoxic action of 4-NC
depended on the pro-apoptotic protein Noxa, which is
able to bind and neutralize Mcl-1. We also demonstrate
the dual role of 4-NC as a potent ROS inducer. The
mechanism of action of this compound, which trans-
passed the chemoresistance of melanoma cell lines in
vitro, is described here in a three-dimensional model of
artificial skin.
Results
4-NC cytotoxicity
We have previously reported the cytotoxic activity of
4-NC (structure shown in Figure 1A) in three human
metastatic melanoma cell lines and the resistance of
normal human fibroblasts to this compound (Brohem
et al., 2009).We now demonstrate that this cytotoxic
activity extends to a greater number of metastatic mela-
noma cell lines, irrespective of mutations in p53, BRAF
and NRas (Figure 1B), but, interestingly, not for a large
panel of human dermal fibroblasts (Supporting Informa-
tion Figure S1).
Production of reactive oxygen species (ROS) and
induction of DNA alterations
Because of the high antioxidant potential attributed to
4-NC (Barros et al., 1996) and the fact that antioxidants
also behave as pro-oxidants under certain conditions,
we began the mechanistic study of the action of this
compound by examining the production of reactive oxy-
gen species (ROS). We measured the activity of two
enzymes involved in the cell antioxidant system, cata-
lase and superoxide dismutase (SOD), which are
responsible for the maintenance of low levels of ROS
and cell homeostasis. As seen in Figure 2A, 4-NC inhib-
ited the action of catalase in both fibroblasts and in mel-
anomas. However, we observed that 4-NC tended to
increase the SOD activity only in fibroblasts and not in
melanoma cell lines.
Figure 2B demonstrates that the production of the
radical superoxide anion (O2 ) by cells is increased in a
4-NC concentration-dependent manner (20, 30, 40, 50
and 100 lM), but each melanoma cell line responds dif-
ferently. In other words, the pro-oxidant response of the
compound depends on the concentration of compound
added. Knowing that this compound could induce ROS
in melanoma cells, we questioned whether the ROS
resulting from 4-NC treatment could induce DNA
lesions. To investigate this, we used 8-oxo-7,8-dihydro-
2¢-deoxyguanosine (8-oxodGuo) as a marker of DNA oxi-
dative damage and phosphorylated histone 2A (cH2AX)
as a marker of global DNA damage. The global DNA
methylation was verified by quantitation of 5-methyl-2¢-
4- NC induces apoptosis via ROS and Noxa in melanoma
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deoxycytidine (5-methyl-dCyd). As shown in Figure 2D,
4-NC induced an increase of 8-oxodGuo and 5-methyl-
dCyd levels in SK-Mel-103, in a dose-dependent
manner. DNA global damage was also investigated
using cH2AX (gamma-H2AX), which can be rapidly phos-
phorylated due to a DNA double-strand break (Celeste
et al., 2003). As seen in Figure 2E, the results of flow
cytometry assay show that 30 lM of 4-NC treatment
was able to increase the levels of cH2AX.
Reactive oxygen species production was also evalu-
ated via flow cytometric measurement of dichlorofluo-
rescein diacetate (DCFH-DA), a well known compound
that quantifies hydrogen peroxide (H2O2) produced intra-
cellularly. This probe also indicated a pro-oxidant profile
following 4-NC treatment, with increases in ROS produc-
tion for all cell lines analyzed (Figure 3). ROS production
was only detected after 12 h of treatment in normal fi-
broblasts, but as early as 2 h after treatment in mela-
noma SK-Mel-28, and production was maintained until
12 h (at 30 lM 4-NC). ROS quantification with the probe
DCFH-DA indicated a difference in profile among the cell
lines tested. Cell lines SK-Mel-103 and SK-Mel-147
showed dramatic ROS peaks at 2 h after treatment,
following both 10 and 30 lM 4-NC treatment, with ROS
decreasing after this period (Figure 3).
We used a potent antioxidant compound polyhydroxilic
di-sodium 4,5-dihydroxybenzene 1,3-disulfonate (Tiron),
which is known to sequester ROS, in order to determine
whether 4-NC-induced ROS was responsible for cell
death in melanoma cell lines. As shown in the rightpanel
in Figure 3, production of H2O2 induced by 4-NC was
greatly reduced in the presence of Tiron. Addition of
Tiron and 4-NC to melanoma cells and normal fibroblasts
almost completely abrogated cell death. Thus, we found
that the production of ROS induced by 4-NC is essential
for its mechanism of action, and that the presence of
Tiron prevented 4-NC-induced cell death by approxi-
mately 45% in the cell lines studied (left panel, Figure 3).
Results regarding Tiron cytotoxic effects are shown in
Supporting Information Figure S2.
Evaluation of protein modulation involved in
apoptotic cell death
We evaluated the effect of 4-NC on p53 protein
(Figure 4) because of the relationship of the nuclear
phosphoprotein p53 with oxidative stress and its key
role in maintaining genome integrity via DNA repair or
removal of damaged cells through apoptosis. 4-NC
caused an increase in p53 protein levels in melanoma
cell lines SK-Mel-103 and SK-Mel-147, which maintain
wild-type p53. As expected, p53 levels in the cell line
SK-Mel-28 (mutant p53) were not altered. Furthermore,
human fibroblasts, which are much less sensitive to
4-NC treatment, demonstrated almost no increase in
p53 under these conditions (see graphic quantification in
Figure 4).
Key regulators of the intrinsic apoptotic pathway were
also analyzed, including the anti-apoptotic Bcl-2 family
members, in the absence or presence of 4-NC. As can
be seen in Figure 5A, 4-NC does not appear to regulate
Bcl-2 and Bcl-xL protein levels in melanoma cell lines.
Conversely, levels of the anti-apoptotic Mcl-1 family
member were increased. Furthermore, 4-NC was able
to further modulate pro-apoptotic proteins of the Bcl-2
family, inducing the cleavage of Bax and Bid as well as
the upregulation of Noxa (Figure 5B).
Interestingly, this increase in both the anti-apoptotic
Mcl-1 (Figure 5A) and pro-apoptotic Noxa (Figure 5B)
reflected a pattern very similar to that exhibited by mel-
anoma cells following treatment with bortezomib, a
known proteasome inhibitor. Using bortezomib as a con-
trol, we discovered that not only were levels of Noxa
and Mcl-1 increased following treatment with 4-NC, but
there was also an accumulation of ubiquitinylated pro-
A B
Figure 1. 4-NC-induced cytotoxicity. (A) Structure of 4-nerolidylcathecol (4-NC). (B) 4-NC cytotoxicity in a panel of human metastatic
melanoma cell lines at 24 h: SK-Mel-19, SK-Mel-28, SK-Mel-29, SK-Mel-103, SK-Mel-147, UACC-62, UACC-257 and WM-1366. Note that 4-NC
shows some cytotoxicity in all cell lines, regardless of mutational status of p53, BRAF(V600) and NRas (exon 3). NT, non-treated.
Magnification 40·.
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teins in the cell extracts, possibly suggesting that 4-NC
acts at the proteasomal level. We extended our analysis
of Bcl-xL, Mcl-1 and Noxa levels to include melano-
cytes, keratinocytes and the p53 mutant melanoma cell
line SK-Mel-28. Comparing these lines with SK-Mel-147,
although 4-NC induced Mcl-1 and Noxa levels to some
degree in all cell lines studied, there was a more dra-
matic induction of Noxa in the sensitive melanoma line
SK-Mel-147 (Supporting Information Figure S3). The
same was shown in the sensitive cell line SK-Mel-103
(Figure 5B).
As the cleavage of Bid and Bax and the increase in
pro-apoptotic Noxa contributed to the alteration of
mitochondrial membrane potential, we utilized a 3,3¢-di-
hexyloxacarbocyanine iodide (DiOC6) probe for mea-
surement of mitochondrial membrane potential by flow
cytometry (Figure 5C). 4-NC induced a change in mem-
brane potential in a dose-dependent manner, showing
a release of mitochondrial cytochrome c and an activa-
tion of the intrinsic apoptotic pathway. This change
was more pronounced in melanoma cell line SK-Mel-
103, which we have shown is more sensitive to 4-NC
treatment (see photos and cell viability in Figure 3).
Immunoblotting demonstrated the cleaved protein
product (35 kDa) of caspase-3, as well as those of cas-
pase-9 (37, 35 and 17 kDa) in melanoma cell lines fol-
lowing 24 h treatment with 30 lM 4-NC (Figure 6A).
Because fibroblasts are more resistant to the action of
4-NC, this cleavage was not observed following treat-
ment with the compound. The drug doxorubicin was
used as a positive control, as it has been widely
described in the literature to induce caspase-dependent
apoptosis.
To verify that the apoptosis induced by 4-NC was
really dependent on caspases, we used the pan caspase
inhibitor zVAD-fmk (carbobenzoxy-valyl-alanyl-aspartyl-
[O-methyl]-fluoromethylketone). In the presence of
zVAD, there is an increase in cell viability even when
cells are treated with 30 lM of 4-NC (Figure 6B). We
also verified the inhibition of caspase cleavage by immu-
noblotting in the presence of zVAD and 4-NC (Fig-
ure 6B).
A
D
E
B
C
Figure 2. 4-NC modulates antioxidant
enzymes, inducing ROS and DNA
damage. (A) Measurement of enzyme
activity for catalase and SOD in fibroblasts
(FF287) and metastatic melanoma cell line
SK-Mel-103 in the presence (10 lM) or
absence (NT) of 4-NC. (B) Lucigenin
detection of superoxide radical (O2 ) after
the addition of 4-NC (20, 30, 40, 50 and
100 lM) in human melanoma cell lines:
SK-Mel-28, SK-Mel-103 and SK-Mel-147.
The analysis was performed following
exposure to 4-NC for 30 min. (C)
Molecular structure of 8-oxodGuo ⁄ 106
dGuo and 5-methyl-dCyd. (D) DNA lesions
induced by 4-NC in SK-Mel-103 measured
by %8-oxodGuo ⁄ 106 dGuo and %5-
methyl-dCyd after the addition of 4-NC (10
and 30 lM). (E) DotPlot and histogram of
cH2AX phosphorylation in SK-Mel-103 NT
and in the presence of 4-NC (30 lM). NT,
non-treated. 10 = treated with 10 lM of
4-NC. 30 = treated with 30 lM of 4-NC.
*P < 0.05; ***P < 0.001.
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Figure 6C demonstrates that the caspase-dependent
apoptosis by 4-NC and Noxa upregulation are related
to ROS production. The joint treatment of Tiron and 4-
NC in SK-Mel-103 does not induce caspase cleavage
or Noxa accumulation. Our results indicate that treat-
ment with 4-NC induces caspase-dependent apoptosis
in the melanoma cell lines studied and also that the
production of ROS induced by 4-NC is essential for its
mechanism of action. In addition, a proteasome inhibi-
tor, MG132, was used as control (cytotoxic results
shown in Supporting Information Figure S4), whose
activity is not influenced by the presence of Tiron; this
led us to perform experiments concerning proteasomal
inhibition.
Identifying 4-NC as a proteasome inhibitor
Interestingly, upon analyzing the key apoptotic regula-
tors by immunoblotting, we discovered that treatment
with 4-NC led to a dramatic increase in the protein lev-
els of Noxa and Mcl-1. This pattern is a similar to that
previously seen in melanoma after bortezomib-induced
cell death (Ferna´ndez et al., 2005, 2006; Nikiforov et al.,
2007). As bortezomib is a proteasome inhibitor, we
decided to investigate the proteasomal activity in the
melanoma cells treated with the 4-NC compound. We
observed a dramatic increase in ubiquitinylated proteins
at both 10 and 30 lM concentrations of 4-NC (Fig-
ure 7A). This is an indication of proteasomal inhibition
and we used bortezomib treatment as a positive control
(shown in far right lane). It is noteworthy that the accu-
mulation of ubiquitinylated proteins in normal fibroblasts,
which are more resistant to 4-NC killing, was much less
dramatic than in melanoma lines.
As shown in Figure 7B, 4-NC was able to inhibit prote-
asomal activity in an extremely significant manner. Mea-
surement of the proteasomal activity via detection of the
fluorophore 7-amino-4-methylcoumarin (AMC) indicated
that SK-Mel-103 and SK-Mel-147 cell lines have higher
levels of proteasome activity as compared with fibro-
blasts and SK-Mel-28. Although there were differences in
proteasomal activity among the cell lines, 4-NC inhibited
the proteasomal activity at 10 and 30 lM in all cell lines.
At the higher concentrations, 4-NC inhibited the protea-
some activity of all cell lines analyzed in a manner very
similar to that of the proteasome inhibitor bortezomib.
To determine whether 4-NC-induced cell death was
dependent on upregulation of Noxa, which in turn could
neutralize high Mcl-1 levels, we used lentiviral vectors
containing shRNAs directed against Noxa to assess the
role of NOXA protein in cell death. As shown in
Figure 7B, 4-NC-induced cell death was almost com-
Figure 3. 4-NC induces ROS production
in melanoma cells. Right: Detection of 4-
NC-induced hydrogen peroxide production
with the probe DCFH-DA by flow
cytometry. Shown is the ROS-dependent
increase in fluorescence (arbitrary units)
versus time for the cell lines FF287, SK-
Mel-28, SK-Mel-103 and SK-Mel-147 after
the addition of 4-NC (10 and 30 lM), Tiron
(1 mM) and mixed (30 lM 4-NC and
1 mM Tiron). We used H2O2 as a control
for the reaction. *P < 0.05 and
**P < 0.001. Left: Optical micrographs of
the cell lines according to the conditions
described above. Control = untreated. Cell
viability in the presence or absence of
each treatment is indicated.
Figure 4. 4-NC-induced p53 stabilization. Evaluation of p53 protein
expression in normal cells: FF287 (fibroblasts); and metastatic
melanomas: SK-Mel-28, SK-Mel-103 and SK-Mel-147, following
4-NC (10 or 30 lM) treatment as compared with non-treated (NT).
The chemotherapeutic agent doxorubicin (0.8 mg ⁄ml) was used as
control. wt, wild-type; mut, mutated p53 gene. The protein actin
was used as a protein quantification control. Quantification of p53
induction by doxorubicin or 4-NC is shown on the right.
*P < 0.05; **P < 0.01.
Brohem et al.
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pletely abrogated following downregulation of Noxa by
shRNA in melanoma line SK-Mel-103. In the absence of
Noxa, 4-NC was unable to induce cell death by apopto-
sis. Cell viability in SK-Mel-103 increased from 51% in
the presence of 30 lM 4-NC to 78% (shNoxa1) and
94% (shNoxa2) upon Noxa inhibition. This demonstrates
the importance of the Noxa gene in the mechanism of
action of 4-NC. We performed Western blotting assays
to detect Noxa protein half-life after 4-NC treatment. 4-
NC induced Noxa accumulation at all time points studied:
3, 6, 12, 24 and 48 h after treatment. In the presence of
Tiron as well, 4-NC was not able to induce Noxa produc-
tion, showing the relation of Noxa accumulation and
ROS (data not shown).
Action of 4-NC in an artificial skin model containing
melanoma
To evaluate the action of 4-NC in a 3D model more clo-
sely reproducing normal skin than in vitro monolayer cell
cultures, we cultivated the metastatic melanoma cell
line (SK-Mel-103) in a model of reconstructed artificial
skin. As shown in Figure 8A, when metastatic mela-
noma is included in the reconstructed artificial skin and
grown with other components of the epidermis (mela-
nocytes and keratinocytes), there is a marked epidermal
hyperplasia due to proliferating melanoma cells. In the
presence of melanoma, the top differentiated epidermal
layers did not appear after 15 days of culture and
numerous melanoma foci grew vertically into the under-
lying dermal layer. (Figure 8, control without melanoma
and NT). When the skin containing melanoma (Figure 8)
was treated with 10 lM of 4-NC for 72 h, the mela-
noma proliferation appeared reduced as compared with
the control, resulting in a thinner epidermal layer with
fewer melanoma foci growing vertically into the dermal
layer (Figure 8, middle panels). Upon treatment with
30 lM of 4-NC, these effects became much more
prevalent. There was a reduced presence of melanoma
proliferation in the epidermis with no vertical growth
observed into the underlying dermal layer (Figure 8,
right panels). The epithelium differentiation markers ker-
atin 14 (Figure 8B) and involucrin (Figure 8C) were used
to identify the basal and upper layers of the skin,
respectively. These markers were used to observe
undifferentiated epithelia, as well as areas of melanoma
growth (arrows) and regression with 4-NC treatment.
Note that in this 3D model, 4-NC was not toxic for nor-
mal keratinocyte cells, once the epidermis was able to
proliferate in the presence of 30 lM of 4-NC.
Discussion
In 1926, the first edition of the Brazilian Pharmacopeia
(Silva, 1926) registered the roots of Pothomorphe um-
bellata L. Miq as a drug that had been used for a long
time in traditional Brazilian medicine. The use of P. um-
bellata in traditional medicine includes the treatment of
several diseases and the pharmacological proprieties of
this plant were attributed to its main compound, 4-nerol-
idylcatechol. The plant extract containing 4-NC has been
long employed, including in the treatment of skin-related
injuries, and the non-toxic effects on normal skin cells
have been noted and described.
4-NC was initially described as a potent antioxidant
(Barros et al., 1996). However, it has more recently been
shown to have cytotoxic potential against human meta-
static melanoma cells (Brohem et al., 2009). The develop-
ment and progression of melanoma can also be the result
of oxidative stress in skin melanocytes (Meyskens et al.,
2001; Nihal et al., 2005), and under certain conditions
antioxidants can act as pro-oxidants (Chandan, 2002;
Dong et al., 2007; Nakazato et al., 2005). Therefore we
hypothesized that 4-NC properties potentially could be
useful for controlling melanoma tumor progression.
A
C
B
Figure 5. 4-NC induces apoptosis and
modulates pro- and anti-apoptotic proteins.
Evaluation of protein expression of (A)
anti-apototic proteins: Bcl-2, Bcl-xL and
Mcl-1, and expression ⁄ cleavage patterns
of (B) pro-apoptotic proteins Bid, Bax and
Noxa, in normal cells: FF287 (fibroblasts)
and metastatic melanoma: SK-Mel-28, SK-
Mel-103 and SK-Mel-147, untreated (NT)
or treated with 4-NC (10 and 30 lM) for
24 h. D, doxorubicin; B, bortezomib, drugs
used as control. b-actin or tubulin proteins
were used as protein quantification
controls. (C) Change of mitochondrial
membrane potential (Dwm) treatment with
4-NC (10 and 30 lM), verification by the
probe DiCO6 (3) by flow cytometry (FITC-
reading). Note the greatest peak change in
the melanoma cell line SK-Mel-103.
*P < 0.05; **P < 0.01;***P < 0.001.
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We initially treated a panel of melanoma cell lines as
well as normal cells with 4-NC to determine the effects
of 4-NC on cell viability. 4-NC induced cell death in all
melanoma cell lines that contained different point muta-
tions in genes such as p53, BRAF and NRas, showing an
important feature of this compound. The treatment lasted
24 h in these studies, confirming the results of Brohem
et al. (2009), which showed the efficacy of 4-NC.
To determine whether 4-NC played any role in ROS
regulation in the melanoma cell lines studied, we
assessed the activity of two enzymes involved in the
REDOX cell system, specifically catalase and superoxide
dismutase (SOD). 4-NC was able to inhibit the enzyme
catalase in fibroblasts and human melanomas. Catalase
is a well conserved enzyme among organisms which
detoxifies hydrogen peroxide into water and oxygen (Nis-
hikawa et al., 2005). Mechanistic studies of compounds
that induce apoptotic cell death via ROS have demon-
strated the importance of inhibition of this enzyme in the
accumulation of ROS and, consequently, cell death by
apoptosis. A study published by Averill-Bates et al. (2008)
showed that polyamine cytotoxicity in murine melanoma
B16-F10 occurs only upon concurrent catalase inhibition,
demonstrating the importance of ROS accumulation in
melanoma cell death (Averill-Bates et al., 2008).
The superoxide anion (O2 ) can result from mitochon-
drial respiratory chain activity, and mitochondria contain
active superoxide dismutase (SOD) (Koch et al., 2004)
to protect mitochondria from damage by free radicals
(Pani et al., 2009a). Therefore, we also analyzed this
enzyme of the antioxidant system. We found that 4-NC
was able to induce an increase of SOD activity in fibro-
blasts but not in melanomas. An increase of antioxidant
enzymes can be associated with suppression of tumori-
genicity and metastatic ability in some tumors (Rieber
and Rieber, 1999). Therefore, the increased SOD activity
in fibroblasts upon 4-NC treatment might explain the
resistance of these cells to 4-NC, i.e. not allowing the
accumulation of superoxide anion radical, and therefore
not causing mitochondrial damage leading to apoptosis.
A
B
C
Figure 6. Caspase-dependent cell death.
(A) Evaluation of caspase-3 and caspase-9
cleavage in normal cells [FF287
(fibroblasts] and metastatic melanomas
(SK-Mel-28, SK-Mel-103 and SK-Mel-147)
following 4-NC (10 or 30 lM) treatment as
compared with non-treated (NT) for 24 h.
E = 1% ethanol control, D = doxorubicin
0.5 mg ⁄ml for 24 h. The protein b-actin
was used as a loading control. (B) Effects
of caspase inhibition as shown by light
microscopy (left panel) on the melanoma
line SK-Mel-103 treated with 4-NC (10 and
30 lM) in the presence and absence of
the pan-caspase inhibitor zVAD-fmk at
24 h. Cell viability as determined by
Trypan Blue exclusion assay is indicated.
Effects on caspase-9 and caspase-3
cleavage patterns are shown by
immunoblotting (right panel) for SK-Mel-
103, in the absence ()) or presence (+) of
zVAD. b-actin was used as a loading
control. (C) Evaluation of caspase-3 and
caspase-9 cleavage in SK-Mel-103, in the
presence (+) or absence ()) of Tiron when
not treated (NT) or treated with 4-NC
30 lM (right panel); and also Noxa
expression levels (left panel) in the same
conditions; the proteasome inhibitor
MG132 (MG) was used as control. a-
Tubulin was used as a loading control.
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Increased ROS generation can lead to biomolecular
damage, which may contribute to cell death. A useful
marker of cell oxidative damage is the lesion 8-ox-
odGuo, generated by guanine one-electron oxidation and
through ·OH radical or singlet oxygen (1O2) attack to the
guanine moiety in DNA (Cadet et al., 2008). The lesion
8-oxodGuo has been widely used as a marker of oxida-
tive stress in epidemiologic and mechanistic studies
(Bianchini et al., 2001; Cadet et al., 2008; Chuang et al.,
2010; Li et al., 2010; Yoshino et al., 2002) and lately
there have been efforts to minimize its artifactual gener-
ation during DNA preparation for analysis (Chao et al.,
2008; ESCODD, 2002; ESCODD et al., 2004; Mangal
et al., 2009; Ravanat et al., 2002). 4-NC (30 lM)
increased by about twofold the levels of 8-oxodGuo in
SK-Mel-103 cells, as measured by HPLC-ESI-MS ⁄MS
(Figure 2D), indicating that ROS production affects cell
DNA, leading to lesions that may trigger apoptosis (Chu-
ang et al., 2010; Li et al., 2010).
This compound caused global DNA damage, increas-
ing the phosphorylation of gamma-H2AX (cH2AX)-posi-
tive cells (Figure 2E). The genotoxic effect of several
substances can be detected by analysis of cH2AX
expression, as is evidenced by the checkpoint response
to DNA double-strand breaks (Gaddameedhi and Sancar,
2011). Clinical samples from cancer patients were evalu-
ated for cH2AX levels, showing that these can be used
as markers for treatment efficiency and prediction of
tumor cell sensitivity to DNA damage of new drugs
(Podhorecka et al., 2010).
A C
B
Figure 7. 4-NC cytotoxicity is dependent on proteasomal activity and Noxa. (A) Protein ubiquitinylation after 24 h of 4-NC treatment (10 or
30 lM). (B) Inhibition of proteasomal activity by treatment with 4-NC. Proteasomal activity is measured by detection of the fluorophore 7-
amino-4-methylcoumarin (AMC). 4-NC was able to inhibit proteasomal activity in all cell lines after 24 h treatment (10 or 30 lM). (C) Optical
microscopy of melanoma SK-Mel-103 following shRNA downregulation of Noxa in the presence or absence of 4-NC treatment (10 or 30 lM)
as compared with non-treated (NT) or bortezomib (Bortz) control. Cell viability as determined by Trypan Blue exclusion assay is indicated at
24 h. Bottom panel indicates quantification of % cell viability for control, uninfected cells; KH1, lentiviral control infected cells; shNoxa 1 and
2, two separate shRNA constructs designed to recognize nucleotides of the Noxa gene, following 4-NC treatment (10 or 30 lM) as compared
to non-treated (NT), or bortezomib (Bortz)-treated. *P < 0.05; ** P < 0.01; ***P < 0.001.
A
B
C
Figure 8. 4-NC inhibits metastatic
melanoma invasion in an artificial skin
model. (A) H&E staining. (B)
Immunostaining for keratin 14 and (C)
involucrin following 4-NC treatment for
72 h. Control – artificial skin without
addition of melanoma. NT – artificial skin
in the presence of melanoma cell line SK-
Mel-103 with no 4-NC treatment, or
treated at concentrations of 10 or 30 lM.
Arrows indicate regions of melanoma
proliferation. (A) 20·, (B) 40·
magnification.
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Besides genotoxicity, 4-NC (30 lM) altered the global
DNA methylation pattern of SK-Mel-103 cells, inducing
DNA global hypermethylation. DNA methylation occurs
in the C-5 position of cytosine and is a stable epigenetic
event crucial for normal proliferation and maintenance
of genomic stability. It is suggested that the DNA meth-
ylation pattern can be changed by exposure to genotox-
ic agents, with transmission of the new pattern to the
subsequent cell generations (Yauk et al., 2008). DNA
methyl-transferases (DNMTs) are the enzymes that
accomplish the C-5 cytosine methylation in DNA. These
enzymes are upregulated when DNA is damaged and
their DNA binding affinity is better when DNA lesions
are present (James et al., 2003). It is hypothesized that
DNMT1 is an ancient DNA repair enzyme conserved
throughout the evolution and its upregulation when
DNA is damaged leads to DNA hypermethylation
(Roberts, 1995; Yauk et al., 2008). DNA hypermethyla-
tion may alter chromatin structure and decrease gene
expression, among other effects (Yauk et al., 2008),
which may change the rates of cell replication and
survival.
An increase in the total amount of ROS was observed
following the treatment with 4-NC in melanoma cell
lines with both detection probes. As a control, the
potent antioxidant Tiron was used in combination with
4-NC. This antioxidant was used because there are
studies that indicate that Tiron can inhibit apoptosis in
melanoma when the melanoma is caused by ROS
induced by cytotoxic compounds, such as bortezomib
(Ferna´ndez et al., 2006), or combination therapies such
as MAPK inhibitor and BH3 mimetics (Verhaegen et al.,
2006). The combination of 4-NC and Tiron reduced cell
death quite dramatically compared with treatment with
4-NC only. This is an indication that the possible mecha-
nism of action of 4-NC begins with the production of
ROS, eventually leading to cell death. The ROS produc-
tion increment begins after 12 h for fibroblast after
treatment, whereas in melanoma it occurs after just 2 h
of 4-NC exposure. This may partially explain the resis-
tance of fibroblasts to this compound at the evaluated
time points, suggesting a possible therapeutic window
for treatment. Among the melanomas, we also
observed profile differences; cell lines SK-Mel-103 and
SK-Mel-147 demonstrated the highest ROS peak at 2 h
after treatment, with levels dropping soon afterwards.
In contrast, there is a constant induction of ROS in cell
line SK-Mel-28 throughout the exposure to 4-NC.
An explanation for this difference may stem from the
fact that SK-Mel-28 has a point mutation in codon 145
of the p53 gene, causing overexpression of a mutant
protein (Girnita et al., 2000; Haapajarvi et al., 1999;
Mousavi-Shafaei et al., 2009), which has been shown to
positively regulate genes crucial for tumor transforma-
tion and maintenance of tumorigenicity in melanoma,
such as insulin-like growth factor I receptor (IGF-IR). In
cells where p53 remains a wild type, the opposite
occurs, i.e. p53 inhibits the transcriptional regulation of
this gene (Girnita et al., 2000). It is also known that p53
is able to induce the production and accumulation of
ROS by promoting mitochondrial oxidative stress via
expression of p66shc protein, generating a mitochon-
drial hydrogen peroxide (Pani et al., 2009a,b). Thus, the
fact that SK-Mel-28 has a gain of function mutation in
p53 possibly leads to an increased accumulation of
ROS, due to the induction of mitochondrial oxidative
stress.
These results indicated a divergent role for 4-NC, not
acting as an antioxidant in this setting, but rather induc-
ing the production of ROS in melanoma cell lines. This
may be because some antioxidants assume the charac-
teristics of a pro-oxidant such as vitamin E and ECGC,
under certain conditions, such as a strong oxidizing envi-
ronment where there is lack of support for the regener-
ation (reduction) of oxidized antioxidants (Chandan,
2002; Dong et al., 2007; Nakazato et al., 2005).
Reactive oxygen species are known to play a role in
the regulation of the intrinsic pathway of apoptosis
(Li et al., 2002; Pani et al., 2009a; Ribeiro et al., 2005;
Sies, 1993). We have previously described the 4-NC
induction of cell death by apoptosis in melanoma cell
lines (Brohem et al., 2009) and we have furthermore
shown that 4-NC induces ROS production (Figure 3) as
well as DNA lesions (Figure 2D, E). We then asked
whether 4-NC was indeed inducing apoptosis via accu-
mulation of the critical tumor suppressor p53, which is
known to have multiple downstream targets that play
key roles in cell death. 4-NC treatment did indeed allow
accumulation of p53 in the melanoma cell lines SK-Mel-
103 and SK-Mel-147, which retain wild-type p53. There
is no accumulation of p53 in normal fibroblasts, and
they are more resistant than 4-NC-induced cells.
Once activated, p53 can induce the expression of
multiple transcriptional downstream targets, including
members of pro-apoptotic Bcl-2 family members such
as BAX, Puma and Noxa. These factors contribute to
changes in mitochondria physiology that favor the
release of cytochrome c and imminent cell death. 4-NC
induced upregulation of the pro-apoptotic protein Noxa,
as well as the cleavage of other pro-members including
Bax and Bid (Figure 5B), a pattern typically seen upon
induction of apoptotic cell death. Opposed to pro-apop-
totic protein functions are the anti-apoptotic Bcl-2 family
members (e.g. Bcl-2, Bcl-xL, Mcl-1) (Gray-Schopfer
et al., 2007; Hersey and Zhang, 2001; Ibrahim and Ha-
luska, 2009; Soengas and Lowe, 2003). 4-NC treatment
had no effect on Bcl-2 and Bcl-xL members. However,
there was an increase in the anti-apoptotic family mem-
ber Mcl-1 in all cell lines tested.
Overexpression of Noxa in many types of cancer is
associated with its localization to mitochondria, leading
to apoptotic cell death. Mcl-1 is an ubiquitin target that
is upregulated when the proteasome is inhibited. How-
ever, Noxa has the ability to bind specifically to Mcl-1,
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hence neutralizing its anti-apoptotic functions and induc-
ing apoptosis (Miller et al., 2009; Nikiforov et al., 2007;
Oda et al., 2000; Ploner et al., 2008). Although treat-
ment with 4-NC was able to induce high levels of Mcl-
1, the accumulation of Noxa in the sensitive melanoma
cell lines studied most likely neutralized this protein,
leading to cell death (Figure 5B).
Increases in pro-apoptotic proteins can lead to
changes in mitochondrial outer membrane potential
(MOMP) with subsequent release of cytochrome c and
activation of downstream signaling in the intrinsic apop-
totic pathway. We observed that 4-NC altered the mito-
chondrial membrane potential more drastically in
melanomas than in normal fibroblasts. This suggests
that there is a release of cytochrome c from the mito-
chondria into the cytoplasm, which together with Apaf-1
and caspase-9 leads to the formation of the apoptosome
and downstream cell death (Soengas and Lowe, 2003).
The proforms of caspases are inactive and when
cleaved in the cytosol, activation occurs, enabling them to
cleave ⁄degrade several proteins that are required for cell
function. Figure 6A shows cleavage of caspase-3 and
caspase-9 in human melanoma lines when treated with
30 lM of 4-NC for 24 h. Because fibroblasts are more
resistant to the action of 4-NC, this cleavage was not
observed when treated with a concentration of the
compound at this time point, indicating a possible thera-
peutic window for treatment. To ensure that caspase
cleavage and activation is required for 4-NC-induced apop-
tosis, assays with a pan-caspase inhibitor known as Z-
VAD-FMK [carbobenzoxy-valyl-alanyl-aspartyl-(O-methyl)-
fluoromethylketone] were performed. This compound can
permeate cells and bind irreversibly to the catalytic site of
caspases, inhibiting the induction of apoptosis. When Z-
VAD-FMK was present, the cells were resistant to 4-NC
action, cell death was reduced and caspase cleavage was
no longer observed (Figure 6B). This proves that 4-NC-
induced cell death occurs in a caspase-dependent fashion.
The fact that, in the presence of Tiron, 4-NC was not
able to induce caspase cleavage and Noxa overexpres-
sion also shows that the ROS production is essential for
4-NC mechanism of action.
Optimal proteasomal function is essential for survival
of melanoma cells (Amiri et al., 2004; Chen et al., 2009;
Ferna´ndez et al., 2006; Wolter et al., 2007), indicating
that targeting proteasomal regulation may be a potential
therapeutic target. Bortezomib (Velcade; Janssen,
Titusville, NJ, USA), a proteasomal inhibitor, has been
widely studied as a possible chemotherapeutic agent in
the treatment of melanoma (Ferna´ndez et al., 2005,
2006; Lecis et al., 2010; Sorolla et al., 2008; Su et al.,
2010; Wolter et al., 2007). Unfortunately, bortezomib
was not as effective and was very toxic in clinical trials
when used as a single agent (Markovic et al., 2005;
Tawbi and Nimmagadda, 2009), which has prompted
the study of combination therapy of this agent with
other chemodrugs (Seeger et al., 2010; Sorolla et al.,
2008; Su et al., 2010). For example, there is an ongoing
phase I ⁄ II trial of melanoma patients with advanced
solid tumors treated with bortezomib and temozolomide
(Su et al., 2010).
As 4-NC induces the accumulation of ubiquitinylated
proteins, with the accumulation of Noxa and Mcl-1, this
led us to test whether 4-NC acts as a proteasome inhibi-
tor in melanoma cell lines. Regarding intracellular prote-
asomal activity, we have shown that 4-NC does indeed
act as a proteasome inhibitor. Melanoma cell lines SK-
Mel-103 and SK-Mel-147 have higher levels of protea-
some activity when compared with normal fibroblasts. 4-
NC was able to inhibit this proteasomal activity even at
the lowest concentration (10 lM) in these two cell lines
and also in SK-Mel-28. At the higher concentration, 4-NC
was able to inhibit the proteasome activity of all cell lines
analyzed in a very similar fashion to bortezomib.
Identification of 4-NC as a proteasomal inhibitor may
also explain the high levels of ROS, as proteasomal
inhibitors can lead to increase in ROS. However, the
mechanism responsible for the generation of ROS after
inhibition of the proteasome is not known. It has been
proposed that the generation of ROS by bortezomib
may be due to induction of superoxide and changes in
the oxidation-reduction pathway due to interference
with mitochondrial electron transport or by endoplasmic
reticulum stress due to accumulation of proteins in this
organelle (Pe´rez-Gala´n et al., 2006).
The pro-apoptotic protein Noxa is the first target
induced by the proteasome inhibitor bortezomib in can-
cer cells (Nikiforov et al., 2007; Wolter et al., 2007). For
this reason, we also tested whether Noxa was essential
for the apoptosis induced by 4-NC. The cells exhibiting
Noxa downregulation were resistant to 4-NC treatment,
implicating this protein as an important target of 4-NC in
melanoma cell lines. With this data, we can now clas-
sify 4-NC as a new proteasome inhibitor triggering apop-
tosis in various metastatic melanoma cell lines
irrespective of background mutations.
An additional point always to consider when studying
and designing novel cancer therapy is that cancer is a het-
erogeneous disease where cell–cell and cell–matrix inter-
actions play an important role in the initiation and
progression of tumor development and metastasis. In the
past few years, 3D culture models have been incorpo-
rated as sophisticated models in the study of tumor biol-
ogy. The 3D assay is becoming the model of choice
because it recreates a species-specific model mimicking
the tumor microenvironment (Brohem et al., 2010; Chioni
and Grose, 2008). For these reasons, we employed this
important model in the study of the effects and mecha-
nism of action of 4-NC in a cell–matrix context. The 4-NC
compound was determined to have no cytotoxic effects
on the dermal equivalent (Supporting Information Fig-
ure S5) but was able dramatically to inhibit melanoma
proliferation after 72 h of treatment and allowed normal
cells to proliferate in the epithelium (Figure 8).
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The data presented show that 4-NC has several capa-
bilities as an anti-tumoral compound and that protea-
some inhibition is only one aspect of the complicated
pharmacology of this compound. PU has been used in
traditional medicine to treat cutaneous injuries, so one
future application for 4-NC could be as a topical therapy
for patients with cutaneous metastases. As this com-
pound works in NRas melanoma cell lines and cutane-
ous NRas mutant melanomas tend to arise in older
patients (Thomas et al., 2007), who are often not good
candidates for surgery or aggressive chemotherapy, 4-
NC could be one approach to local disease control.
Local lesion destruction through the induction of
apoptosis can also be beneficial, as it can enhance
immune recognition of the untreated lesions, the so-
called bystander effect (BE). This effect is mediated by
cytokines and ROS released from cancer cells (Merle
et al., 2008). For instance, in murine experiments, after
treatment of primary tumors with chloroethylnitrosourea
(CENU), an anticancer agent that acts via DNA damage,
secondary tumors that were not treated exhibited
growth inhibition and metabolism disorders. In other
words, the secondary untreated tumor response was
considered the chemotherapy-induced bystander effect
(Demidem et al., 2010; Merle et al., 2008).
In conclusion, we have shown that 4-NC, a compound
isolated from the Brazilian plant P. umbellata, has the
ability to transpass the resistance of multiple melanoma
cell lines, despite the presence of distinctive mutations
in genes conferring resistance to apoptosis. 4-NC
induced cytotoxicity in a panel of melanomas via induc-
tion of ROS, DNA damage, increased levels of p53 and
Noxa, alterations in mitochondrial membrane potential,
and ultimately caspase-dependent apoptosis. In addition,
we have now uncovered a previously unknown role for
4-NC in proteasomal inhibition. Furthermore, we have
shown that 4-NC inhibited melanoma proliferation in a
3D model of artificial skin. Our data explain the mecha-
nism of action of this compound in induction of apoptotic
cell death in melanoma and also as a new proteasomal
inhibitor which can induce cell death in melanoma.
Methods
4-Nerolidylcatechol isolation
4-NC was isolated from the crude extract of P. umbellata as
described by Desmarchelier et al. (2000) and Gustafson et al.
(1992). The freeze-dried ethanol:water (1:1, v ⁄ v) crude extract
(10 g) was submitted to a 60 H silica-gel (0.063–0.100 mm)
chromatography column (15 mm i.d. · 230 mm) and eluted with
CHCl2 (Merck, Darmstadt, Germany) at 23 ml ⁄min in a Buchi flash
chromatography liquid system (Switzerland). TLC (thin-layer
chromatography) was used to detect the 4-NC, comparing it with
the previously isolated 4-NC as a standard and dichlorome-
thane:methanol (91:1 v ⁄ v) as the mobile phase. 4-NC (100% purity)
was isolated using a Shimadzu SCL 10AVP HPLC system (Kyoto,
Japan) equipped with a UV ⁄ VIS detector (SPD10A VP–diode array),
CLASS VP software and a Phenomenex Luna C18 (2) column
(Torrance, CA, USA) (10 lm, 250 mm · 10 mm i.d.). The mobile
phase used was 9:1 MeOH (Merck): H2O with a flow rate of
6.0 ml ⁄min followed by detection at 282 nm. The structure of 4-NC
was deduced by nuclear magnetic resonance 1H (300 MHz), 13C
(75 MHz) and spectral features were compared with published val-
ues (Kijjoa et al., 1980; Ropke et al., 2006).
Cell culture
The metastatic melanoma cell lines used in this work were kindly
donated by Dr. Marı´a S. Soengas (Melanoma Group, CNIO, Spain).
They are denominated as: SK-Mel-19, SK-Mel-28, SK-Mel-29,
SK-Mel-103, SK-Mel-147, UACC-62, UACC- 257 and WM-1366.
Primary cultures of skin cells (keratinocytes, melanocytes and fibro-
blasts) were obtained from the foreskins of University Hospital
(Hospital Universita´rio – HU-USP) patients, donated by Dr. Linda
Maximiano. To this end, the project has undergone review and
approval by the Ethics Committee of HU (HU no. CEP Case
943 ⁄ 09). Melanoma cells and fibroblasts were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 50 U ⁄ml penicillin and 50 lg ⁄ml streptomycin.
The keratinocytes were maintained in Epilife media (SKU #
M-EPICF-500; Cascade Biologics, Portland, OR, USA) supple-
mented with human keratinocyte growth supplement (HKGS – SKU
# S-001; Cascade Biologics). The melanocytes were maintained in
254CF media (SKU # M-500-254CF; Cascade Biologics) supple-
mented with human melanocyte growth supplement (HMGS – SKU
# S-002-5; Cascade Biologics). All cells were maintained at 37C
under 5% CO2 atmosphere. The pure 4-NC was dissolved in 100%
ethanol at a concentration of 10 mM and stored at )20C. The eth-
anol concentration never exceeded 0.1% in culture and showed
100% cell viability when used as a control.
Measurement of cell viability
A total of 5 · 104 cells from each cell line were plated for a 24-h
attachment period followed by treatment with 4-NC (10 or 30 lM).
Cell viability was assessed by standard Trypan Blue exclusion assay
24 h after incubation with the compound by counting live versus
dead cells on a hemocytometer chamber using Trypan Blue (0.4%
in phosphate-buffered saline, PBS) exclusion staining. The assay
was done in quadruplicate. IC50 values (i.e. the concentration that
inhibited cell growth by 50% compared with untreated controls)
were obtained by non-linear regression analysis with GRAPHPAD PRISM
(GraphPad Software, San Diego, CA, USA).
Analysis of the activity of enzymes involved in
cellular antioxidant system
The melanoma cell line SK-Mel-103 and fibroblasts were plated at
8 · 105 cells in a 100 mm2 plate. After a 24-h attachment period,
4-NC was added for a 24-h incubation period. The total protein
was extracted in phosphate buffer containing 0.5 mM EDTA. For
measurement of catalase activity, 100 mM EDTA plus Tris buffer
pH 8.0 were added to 30 lg of sample. Following the addition of
6% (v ⁄ v) H2O2 solution, samples were read for 5 min (at 1-min
intervals) at 230 nm (30C). The activity value represents the
amount of catalase required to hydrolyze 1 lmol H2O2 ⁄min. For
SOD activity measurement, 0.05 M phosphate buffer (pH 7.8)
solution containing 1 mg ⁄ml xanthine, 1 mg ⁄ml KCN, 100 mM
EDTA and 2 mg ⁄ml cytochrome c were added to the samples
described above. To finish, xanthine oxidase (1.82 U ⁄ml) was
added and the samples read for 5 min (at 1-min intervals) at
550 nm (25C). The activity value represents the amount of SOD
required to inhibit 50% of the xanthine oxidase reaction. All read-
ings were made in a BIOTEK plate reader (Bio Tek Instruments
Inc., Winooski, VT, USA).
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DNA extraction and hydrolysis
Cell DNA was isolated as described in the Puregene Gentra pro-
tocol (Qiagen, Valencia, CA, USA) with some modifications. Briefly,
cells of one culture dish (approximately 1 · 107 cells) were resus-
pended in the culture medium without FBS and centrifuged at
300 g for 5 min. The supernatant was discarded and the pellet was
resuspended in 3 ml of Puregene cell lysis solution. RNase A (30 ll
of a 15 mg ⁄ml solution) was added to the cell lysate and, after 1 h
at 37C, protein was precipitated by addition of 1 ml of Puregene
protein precipitation solution and centrifugation at 2000 g for
10 min. The supernatant was poured into a tube containing 5 ml of
cold 2-propanol and the precipitated DNA was collected by centrifu-
gation at 2000 g for 3 min. The DNA was then washed with 3 ml
of 70% ethanol, dried, and resuspended in 200 ll of 0.1 mM desfe-
roxamine solution. DNA concentration was determined by measur-
ing UV absorption at 260 nm, and DNA purity was assessed by the
UV absorbance ratio at 260 ⁄ 280 nm. For the enzymatic hydrolysis,
30-lg aliquots of DNA samples in 0.1 mM desferoxamine solution
were added to 3.75 ll of Tris–HCl ⁄MgCl2 buffer (200 mM, pH 7.4),
6.5 units of DNase I, and 2000 fmol of [15N5]8-oxodGuo. The sam-
ples were incubated at 37C for 1 h. Phosphodiesterase I (0.005
units) and alkaline phosphatase (6.5 units) were then added and
the incubation was continued for another 1 h at 37C. At the end
of the second incubation, the final volume (100 ll) was centrifuged
at 9300 g for 10 min. Aliquots of 50 ll were injected in the HPLC-
ESI-MS ⁄MS-MRM system for quantitation of 8-oxodGuo. Concomi-
tantly, 6 ll of the hydrolyzed DNA solution was injected in the
HPLC-UV system for quantitation of 5-methyl-dCyd and normal de-
oxynucleosides. The analytical systems and the chromatographic
conditions are described below.
8-Oxo-7,8-dihydro-2¢-deoxyguanosine analysis
through HPLC-ESI-MS ⁄MS
The levels of 8-oxodGuo in DNA samples were analyzed by HPLC-
ESI-MS ⁄MS-MRM. The analytical system consisted of an Agilent
1200 series HPLC (Wilmington, DE, USA) equipped with a binary
pump (Agilent 1200 G1312B), an isocratic pump (Agilent 1200
G1310A), a column oven (Agilent 1200 G1316B), a diode array detec-
tor (Agilent 1200 DAD G1315C) and an auto sampler (G1367C Agilent
1200) interfaced with a Linear Quadrupole Ion Trap mass spectrome-
ter, Model 4000 QTRAP (Applied Biosystems ⁄MDS Sciex Instru-
ments, Foster City, CA, USA). The ESI-MS parameters were set in
the positive ion mode as follows: curtain gas, 20 psi; ion source gas,
50 psi; collision-induced dissociation gas, low; ESI probe tempera-
ture, 550C; declustering potential, 46 V; entrance potential, 10 V;
collision energy, 17 eV; collision cell exit potential, 52 V; and ion
spray voltage, 5500 V. Analyses were carried out with multiple reac-
tion monitoring (MRM) using the m ⁄ z 284 (MH+) ﬁ m ⁄ z 168 (MH+-
2¢-deoxyribose+H) fragmentation for 8-oxodGuo andm ⁄ z 289 (MH+)
ﬁ m ⁄ z 173 (MH+-2¢-deoxyribose+H) fragmentation for [15N5]8-ox-
odGuo. The calibration curve was constructed at the interval of
0–250 fmol of 8-oxodGuo, with a fixed amount of [15N5]8-oxodGuo
(1000 fmol). The data were acquired and processed using ANALYST
software 1.4 (Applied Biosystems ⁄MDS Sciex). The molar fraction 8-
oxodGuo ⁄ dGuo present in each DNA sample was determined. The
following chromatography conditions were used for the analyses. A
50 · 2.0 mm i.d., 2.5 lm, Luna C18(2)-HST column (Phenomenex)
with a C18(2) security guard cartridge 4.0 · 3.0 mm i.d. (Phenome-
nex) was eluted with a gradient of 0.1% formic acid (solvent A) and
methanol containing 0.1% formic acid (solvent B) at a flow rate of
150 ll ⁄min and at 25C, as follows: from 0 to 25 min, 0–15% of sol-
vent B; 25–28 min, 15–80% of solvent B; 28–31 min, 80% of solvent
B; 31–33 min, 80–0% of solvent B; 33–46 min, 0% of solvent B. The
first 16 min of eluant was directed to waste and the 16–32 min
fraction was diverted to a second column [150 · 2.0 mm i.d.,
3.0 lm, Luna C18(2)] connected to the ESI source and conditioned
by a third isocratic pump with a solution of 15% methanol in water
containing 0.1% formic acid. The lesion 8-oxodGuo eluted from the
second column at approximately 36 min. All solvents used were pre-
viously filtered and degassed.
Analysis of DNA global methylation through HPLC-
UV
The quantitation of 5-methyl-dCyd and normal 2¢-desoxynucleosides
was carried out with a Shimadzu HPLC system equipped with two
LC-20AT pumps, a photo diode array detector (PDA-20AV), an auto-
injector (Proeminence SIL-20AC), and a column oven (CTO-
10AS ⁄ VP) controlled by a CBM-20A communication module and
the software LC-Solution. Elution system was as follows: a
250 mm · 4.6 mm i.d., 5 lm, Luna C18(2) column (Phenomenex)
attached to a C18(2) guard column (4.0 · 3.0 mm i.d., 4 lm, Phe-
nomenex), eluted with a gradient of formic acid 0.1% and CH3OH
(from 0 to 25 min, 0–18% CH3OH; from 25 to 27 min, 18–0%
CH3OH; from 27 to 37 min, 0% CH3OH) at a flow rate of 1 ml ⁄min
and 30C. The PDA detector was set at 286 nm for 5-methyl-dCyd
and at 260 nm for normal 2¢-desoxynucleoside quantitation. Calibra-
tion curves were constructed at intervals of 0.005–0.05 nmol for 5-
methyl-dCyd and 0.05–1 nmol for dCyd and dGuo. The percentage
of DNA global methylation was calculated using the following equa-
tion: 5-methyl-dCyd (%) = nmol 5-methyl-dCyd · 100 ⁄ (nmol 5-
methyl-dCyd + nmol dCyd).
ROS detection by lucigenin
To assess ROS production, we used a chemiluminescent lucigenin
probe for superoxide anion detection. Specifically, 106 cells were
plated and then collected by trypsinization after 24 h of 4-NC treat-
ment. The cells were centrifuged (1610 g for 5 min. TA), washed
with PBS containing 0.5% glucose, re-centrifuged (1610 g for
5 min. TA) and diluted with PBS-0.5% glucose in the presence or
absence of 4-NC, followed by addition of 0.1 mM lucigenin (bis-N-
methylacridiniumnitrate). Subsequently, the cells were placed in a
96-well white opaque plate and the luminescence was read in a
Berthold 9505 luminometer (EG & Instruments GmbH, Munich,
Germany) every 2 min. Results were integrated and subsequently
analyzed in Microsoft EXCEL.
2¢,7¢-Dichlorofluorescein-diacetate
Alternatively, for ROS detection, 2 · 105 cells were seeded and
samples were collected by trypsinization after 30 min, 2, 4, 6 and
12 h of incubation with 4-NC and 100 lM DCFH-DA (2¢,7¢-dichlorflu-
orescein-diacetate; Sigma, St. Louis, MO, USA). The pellets were
washed and resuspended in PBS for analysis by flow cytometry.
The fluorescence of DCFH-DA was measured in the FITC-FL1 chan-
nel (530 ⁄ 30 nm green fluorescence) of a BD FACs CANTO TM II
(BD, Biosciences, Bedford, MA) flow cytometer and results were
integrated and subsequently analyzed in Microsoft EXCEL.
Flow cytometric analysis of c-H2AX
Cells treated with 4-NC (30 lM) were collected by trypsinization
and fixed in fresh 2% formaldehyde at 4C for 15 min. The fixed
cells were centrifuged at 11450 g for 10 min and washed once
with PBS. They were resuspended in ice-cold 70% ethanol and
kept at )20C overnight. The cells were centrifuged and perme-
ated ⁄ blocked in PBS containing 0.2% Triton X-100 and 1% bovine
serum albumin (BSA-T-PBS) at room temperature for 5 min. Cells
were incubated with anti-phospho Ser139-H2AX mouse monoclonal
antibody (05-636, 1 ⁄ 300, Millipore, Billerica, MA, USA) at room
temperature for 1 h. After washing in BSA-T-PBS, they were incu-
bated with anti-mouse Alexa Fluor 488-conjugated IgG goat anti-
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body (A-10684, 1 ⁄ 200, Invitrogen, Carlsbad, CA, USA) at room tem-
perature for 1 h. The fluorescence intensity of FITC was deter-
mined using a FACs CANTO TM II flow cytometer (BD
Biosciences, Bedford, MA, USA) and the results were analyzed
with FLOWJO software v. 8.8.2 (Tree Star, Ashland, OR, USA). At
least 10 000 cells per sample were analyzed.
Western blotting
To detect alterations in protein levels, 2 · 106 cells were treated
with 4-NC (10 or 30 lM), Doxorubicin (0.6 lg ⁄ml; Fisher, Fair
Lawn, NJ, USA), bortezomib (50 nM, Millennium Pharmaceuticals
Inc., Osaka, Japan), MG132 (5 lM; C2211, Sigma-Aldrich Corp.,
St. Louis, MO, USA) or z-VAD-fmk (20 nM; Millennium Pharmaceu-
ticals Inc.) and harvested 24 h after treatment. Total cell lysates
were obtained with Laemmli Buffer (10% SDS, 0.0625 M Tris-HCl
pH 6.8, 10% glycerol, and 5% 2-beta-mercaptoethanol) extraction.
Total protein, 30 lg was subjected to electrophoresis in 12, 15 or
4–15% gradient SDS gels under reducing conditions, and subse-
quently transferred to polyvinylidene difluoride (PVDF) membranes
(Hybond-P, Amersham Pharmacia Biotech, Piscataway, NJ, USA).
The membranes were incubated with the following antibodies:
actin (A5316, Sigma); Bax (2772, Cell Signaling, Beverly, MA, USA);
Bcl-2 (2876. Cell Signaling), Bcl-xL (610211, BD Biosciences); Bid
(2002, Cell Signaling), caspase-3 (9662, Cell Signaling), caspase-9
(9502, Cell Signaling), Mcl-1 (SC-819, Santa Cruz, St. Louis, MO,
USA); Noxa (114C307, Calbiochem ⁄Merck KGaA, Darmstadt, Ger-
many); p53 (VP-P955, Vector, Burlingame, CA, USA), tubulin
(T6199; Sigma), and ubiquitin (SPA205, Stress Gene, San Diego,
CA, USA). Protein bands were detected by enhanced chemilumi-
nescence system ECL (Amersham Pharmacia Biotech).
Determination of mitochondrial membrane potential
by flow cytometry
To determine the mitochondrial membrane potential, 2 · 105 cells
were plated and, after a 24-h attachment period, 4-NC was added
as described above, followed by addition of DiCO 6(3) (3,3¢-dihexyl-
oxacarbocyanine iodide, Sigma) 30 min prior to collection. Samples
were collected by trypsinization. The pellets were washed and
resuspended in PBS for flow-cytometric analysis. The fluorescence
of DiCO 6(3) was measured in the FITC-FL1 channel (green fluores-
cence, excitation at 488 nm and emission at 525 nm) of a BD FACs
CANTO TM II (BD Biosciences) flow cytometer. Results were inte-
grated and subsequently analyzed in Microsoft EXCEL.
Proteasome inhibition assay
The proteasome activity was measured by the 20S Proteasome
Activity Assay Kit (APT 280; Chemicon-Millipore, Billerica, MA,
USA), following the manufacturer’s instructions. The assay is based
on detection of the fluorophore 7-amino-4-methylcoumarin (AMC)
after cleavage from the labeled substrate LLVY-AMC. After treat-
ment with 4-NC for 24 h, the cells were collected by scraping and
were washed twice with cold PBS. The pellet was lysed with
0.5 ml lysis buffer [50 mM HEPES (pH 7.5), 5 mM EDTA, 150 mM
NaCl and 1% Triton X-100] for 30 min on ice, with vortexing at
10-min intervals. The lysate was centrifuged at 23900 g for 15 min
at 4C. As samples, 30 lg of the lysates were used and the protea-
some substrate was added. Lactacystin (250 nM) was added to the
control lysate as a negative control 15 min prior to the proteasome
substrate addition. Samples were incubated for 1 h at 37C and the
free AMC fluorescence was quantified at 380 ⁄ 460 nm in a Bio
Tek fluorometer (Bio Tek Instruments Inc.). As an internal control
of the experiment, the drug lactacystin was used in the NT cell
extracts to show that the cells have functional proteasome activity
(data not shown).
Lentiviral infections
To inhibit Noxa expression, the melanoma cell line SK-Mel-103 was
infected with shRNA lentiviral particles designed to downregulate
Noxa, which were kindly donated by Dr. Marı´a S. Soengas (CNIO,
Spain). The sequences of the shRNA lentiviral vectors used in this
work have been reported previously (Ferna´ndez et al., 2005). Treat-
ment with 4-NC was initiated 3 days after infection with virus con-
taining shRNA sequences.
Artificial skin reconstruction
To manufacture the artificial skin reconstructs, we followed Boc-
cardo et al. (2004) with the modifications described below. The der-
mal equivalent was prepared with 1.5 · 105 fibroblasts embedded
in a type I collagen (BD Biosciences) matrix. After dermal equiva-
lent polymerization, 1.5 · 105 keratinocytes, 104 melanocytes and
104 melanoma cells were plated above the dermal layer. Following
contraction of the collagen gel, the entire structure was transferred
to a steel grid to allow for an air–liquid interface while maintaining
contact with the raft medium consisting of 67.5% DME, 22.5%
Ham’s F12; 10% fetal calf serum, 5 lg ⁄ml apo-transferrin (T-1147;
Sigma), 5 lg ⁄ml insulin (I-1882; Sigma), 0.4 mg ⁄ml hydrocortisone
21-hemisuccinate (H-4881; Sigma), 1 ng ⁄ml EGF (human epidermal
growth factor, 13247-010; Gibco ⁄ Invitrogen) and 0.1 nM cholera
toxin (3012; Sigma). After 2 weeks at the interface, 4-NC was
added for an additional 72 h. The skin reconstructs were washed
with PBS pH 7.4 and embedded in paraffin for histological analysis.
Immunohistochemical staining
After deparaffinization and rehydration, antigen retrieval was carried
out with Tris-EDTA, pH 9.0 (S3307; DAKO, Carpinteria, CA, USA),
in a water bath heated with steam and held at 97C for 30 min.
Slides were cooled to room temperature for 20 min, washed with
distilled water and TBST buffer (Tris-buffered saline with 0.01%
Tween-20, 3306, Dako). The slides were blocked with 2% BSA
for 2 h at 37C. The primary antibodies keratin 14 (ab7800 Abcam,
Cambridge, MA, USA) and involucrin (ab27495; Abcam) were
diluted 1:100 in 2% BSA. The Fast-Red Substrate Kit (ab64253; Ab-
cam) or ARK (Animal Research Kit, K3954– Dako) were used for
detection purposes. Primary antibody was omitted for negative
controls.
Statistical analysis
All data is expressed as the mean ± SEM, except 8-oxodGuo, which
are expressed as the mean ± SD. GRAPH PAD INSTAT software (version
3.01 for Windows XP; Graph Pad Software, San Diego, CA, USA)
was used to perform statistical analyses. One-way ANOVA with a Tu-
key–Kramer multiple comparison test was used for data analyses.
We used the correlation analyses potentially to identify causal asso-
ciations between variables. For cytotoxicity experiments, the statisti-
cal analyses were performed using GRAPH PAD PRISM 4 (version 4.00
for Windows Vista; Graph Pad Software) software, and the two-way
ANOVA test was performed for data analyses.
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